Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

0.6768 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.6768
Bid (Size) 0.6484 (2)
Ask (Size) 0.8998 (23)
Prev. Close 0.6768
Today's Range 0.6768 - 0.6768
52wk Range 0.6516 - 5.265
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Analyst Ratings for Sangamo Therapeutics
Via Benzinga

Performance

YTD
-78.45%
-78.45%
1 Month
-18.85%
-18.85%
3 Month
-42.64%
-42.64%
6 Month
-60.19%
-60.19%
1 Year
-85.84%
-85.84%

More News

Read More
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
From Sangamo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
A Preview Of Sangamo Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings for Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics's Return On Capital Employed Overview
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
From Sangamo Therapeutics, Inc.
Via Business Wire
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
Soon After Novartis & Biogen Walked Away From Neurology Drug Partnerships, Sangamo Announces Major Restructuring
Via Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.